Pfizer (PFE)

BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current medical recommendations.

Investors were cheered by two pieces of good news concerning the biotech's most famous product.

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a niche segment has exploded into a multi-billion-dollar arena, driven by highly effective new medications, primarily GLP-1 receptor agonists, that are

Pfizer's own GLP-1 drug candidate failed earlier this year -- so it's buying someone else's.

Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Monday. Discover the stocks that are generating the highest trading volume and driving market activity.

Metsera stock skyrocketed 62% as Pfizer struck a $4.9 billion acquisition agreement focused on obesity therapies.

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on the burgeoning market for weight-loss and diabetes drugs, driven by its groundbreaking GLP-1 agonists. In stark contrast, Johnson & Johnson (NYSE:

The company is focusing on RNA sequencing as a means of assisting with drug development.

These stocks share several common denominators, including attractive valuations.

The deal follows two high-profile failures for Pfizer, which is trying to broaden its small pipeline in weight loss.

Pfizer will buy Metsera for $4.9 billion plus milestone payments, adding incretin, amylin, and oral obesity drug candidates to its pipeline.

Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ: MTSR), a developer of anti-obesity drugs.

The upfront purchase price of $47.50 per share implies a premium of 43% from Metsera’s closing share price on Friday.

Trump administration to announce concerns about Tylenol use in pregnancy and potential treatment for autism, in line with President's priority.

If every one of your dollars counts, make sure you're getting the biggest possible bang for your buck.

There is a "for sale" sign on the sector, and these two stocks look particularly attractive at their current levels.

A high yield is only one part of the story when it comes to picking dividend stocks.

These stocks are bargains now. But they probably won't be by the end of this decade.

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving market demands. New drug developments, particularly in sophisticated biologics, groundbreaking gene therapies, and blockbuster obesity treatments, are fundamentally altering therapeutic paradigms. Simultaneously, the pervasive integration of

Moderna stock toppled Friday after advisors to the CDC and Prevention ended the universal recommendation for Covid vaccines.

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic forecasts are largely fueled by the unprecedented success of its incretin-based medications, Mounjaro and Zepbound, which have become dominant

The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like peptide-1) market. This fierce competition, fueled by blockbuster drugs for diabetes and weight loss, is not merely a corporate rivalry; it's a pivotal